Celgene

Big News Is Fast Approaching for Celgene
Big News Is Fast Approaching for Celgene
Motley Fool
Celgene
luspatercept
beta thalassemia
MDS
Flag link:
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
Biopharma Dive
Celgene
JCAR017
liso-cel
CAR-T
B-cell non-Hodgkin lymphoma
ASCO 2018
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:
Celgene tries to convince investors with 2-billion-dollar program
Celgene tries to convince investors with 2-billion-dollar program
GoinPharma
Celgene
stock buyback
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
After AL amyloidosis flop, Prothena slashes workforce by 57%
After AL amyloidosis flop, Prothena slashes workforce by 57%
Fierce Biotech
Prothena
R&D
Celgene
AL amyloidosis
layoffs
Flag link:
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
Flag link:
Celgene, stricken by setbacks, bids a quiet goodbye to dealmaking czar Golumbeski
Celgene, stricken by setbacks, bids a quiet goodbye to dealmaking czar Golumbeski
Fierce Pharma
Celgene
George Golumbeski
Flag link:
FDA calls out 39 drug companies for allegedly blocking access to generics
FDA calls out 39 drug companies for allegedly blocking access to generics
Stat
JNJ
Actelion
Celgene
Gilead
Novartis
Pfizer
Valeant Pharmaceuticals
generics
FDA
Flag link:
Celgene Starts the Year With a Bang
Celgene Starts the Year With a Bang
Motley Fool
Celgene
earnings
Flag link:
Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A
Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A
Endpoints
Receptos
Celgene
Marcus Boehm
Escient
G-protein coupled receptors
Flag link:
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Fierce Pharma
physicians
digital marketing
Bristol-Myers Squibb
Biogen
Celgene
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
Celgene Rises As Q1 Earnings, Sales Top Views
Celgene Rises As Q1 Earnings, Sales Top Views
Investors Business Daily
Celgene
earnings
Flag link:
Earnings Preview: What To Expect From Celgene On Friday
Earnings Preview: What To Expect From Celgene On Friday
Forbes
Celgene
earnings
Flag link:
4 Huge Pharma Deals in 4 Months Is Just the Beginning
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
M&A
Takeda
Shire
Novartis
AveXis
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:

Pages